251947-21-4

Basic information

• Product Name: tert-Butyl (1R*,4R*)-4-acetamidocyclohexylcarbamate
• Synonyms: tert-Butyl (1R*,4R*)-4-acetamidocyclohexylcarbamate;TERT-BUTYL (TRANS-4-ACETAMIDOCYCLOHEXYL)CARBAMATE
• CAS NO: 251947-21-4
• Molecular Formula: C₁₃H₂₄N₂O₃
• Molecular Weight: 256.34126
• Mol File: 251947-21-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-Butyl (1R*,4R*)-4-acetamidocyclohexylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl (1R*,4R*)-4-acetamidocyclohexylcarbamate(251947-21-4)
• EPA Substance Registry System: tert-Butyl (1R*,4R*)-4-acetamidocyclohexylcarbamate(251947-21-4)

Safety Data

• Hazardous Substances Data: 251947-21-4(Hazardous Substances Data)

Upstream product

• 75-36-5 acetyl chloride 
• 177906-48-8 trans-N-Boc-1,4-cyclohexanediamine 
• 108-24-7 acetic anhydride 

Downstream Products

• 873537-24-7 N-(trans-4-aminocyclohexyl)acetamide trifluoroacetic acid salt 

Relevant articles and documents

FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

Provided are compounds according to any of Formula (I-1) to (I-7), pharmaceutical compositions comprising at least one of said compounds, their use as a medicament, and their use in treating chronic hepatitis B virus (HBV) infection. Methods for preparing compounds according to any of Formula (I-1) to (I-7) are also provided.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY

To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: -CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].